Denali Therapeutics, Inc. (DNLI)
18.64
-1.42
(-7.08%)
USD |
NASDAQ |
Apr 29, 16:00
18.97
+0.33
(+1.77%)
After-Hours: 20:00
Denali Therapeutics Research and Development Expense (TTM) : 418.78M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Biogen, Inc. | 1.498B |
| Neurocrine Biosciences, Inc. | 1.016B |
| Protalix Biotherapeutics, Inc. | 19.57M |
| Arcturus Therapeutics Holdings, Inc. | 95.30M |
| Agenus, Inc. | 79.34M |